TMO
Thermo Fisher Scientific Inc. NYSE Listed Mar 17, 1980$474.34
Mkt Cap $176.3B
52w Low $385.46
34.4% of range
52w High $643.99
50d MA $492.63
200d MA $527.54
P/E (TTM)
26.4x
EV/EBITDA
21.7x
P/B
3.3x
Debt/Equity
0.8x
ROE
12.6%
P/FCF
34.6x
RSI (14)
—
ATR (14)
—
Beta
0.97
50d MA
$492.63
200d MA
$527.54
Avg Volume
2.2M
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
168 Third Avenue · Waltham, MA 02451 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | AMC | 5.25 | 5.44 | +3.6% | 466.70 | +0.5% | +0.6% | +0.3% | +0.8% | -0.1% | +2.6% | — |
| Jan 29, 2026 | AMC | 6.45 | 6.57 | +1.9% | 592.16 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% | — |
| Oct 22, 2025 | AMC | 5.50 | 5.79 | +5.3% | 567.20 | +0.1% | +0.8% | +0.9% | -0.6% | -1.7% | -1.6% | — |
| Jul 23, 2025 | AMC | 5.23 | 5.36 | +2.5% | 466.71 | -0.0% | +1.8% | +2.5% | +3.9% | +3.3% | +2.3% | — |
| Apr 23, 2025 | AMC | 5.10 | 5.15 | +1.0% | 431.64 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% | — |
| Jan 30, 2025 | AMC | 5.94 | 6.10 | +2.7% | 606.74 | -1.1% | -1.5% | -2.1% | -4.3% | -4.0% | -5.6% | — |
| Oct 23, 2024 | AMC | 5.25 | 5.28 | +0.6% | 576.49 | -0.7% | -3.3% | -3.8% | -4.2% | -5.0% | -4.5% | — |
| Jul 24, 2024 | AMC | 5.12 | 5.37 | +4.9% | 574.73 | +0.2% | +3.4% | +5.6% | +5.1% | +7.0% | +6.7% | — |
| Apr 24, 2024 | AMC | 4.71 | 5.11 | +8.5% | 577.39 | +0.0% | -1.0% | -0.7% | -0.1% | -1.5% | -0.4% | — |
| Jan 31, 2024 | AMC | 5.64 | 5.67 | +0.5% | 538.98 | +0.6% | +2.5% | +2.4% | +2.3% | +4.0% | +2.5% | — |
| Oct 25, 2023 | AMC | 5.61 | 5.69 | +1.4% | 433.18 | -0.5% | +1.6% | -0.4% | +0.2% | +2.7% | +1.8% | — |
| Jul 26, 2023 | AMC | 5.43 | 5.15 | -5.2% | 574.41 | +0.2% | -2.5% | -2.2% | -4.5% | -5.0% | -3.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Stifel | Maintains | Buy → Buy | — | $466.70 | $469.15 | +0.5% | +0.6% | +0.3% | +0.8% | -0.1% | +2.6% |
| Apr 24 | Baird | Maintains | Outperform → Outperform | — | $466.70 | $469.15 | +0.5% | +0.6% | +0.3% | +0.8% | -0.1% | +2.6% |
| Apr 14 | Barclays | Maintains | Overweight → Overweight | — | $514.23 | $516.34 | +0.4% | +2.5% | +3.4% | +0.3% | +2.4% | +2.3% |
| Apr 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $491.46 | $492.00 | +0.1% | -0.7% | -0.4% | +2.4% | +1.8% | +0.9% |
| Jan 30 | Barclays | Maintains | Overweight → Overweight | — | $592.16 | $581.73 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% |
| Jan 30 | TD Cowen | Maintains | Buy → Buy | — | $592.16 | $581.73 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% |
| Jan 30 | Citigroup | Maintains | Buy → Buy | — | $592.16 | $581.73 | -1.8% | -2.3% | -1.8% | -3.7% | -4.5% | -8.4% |
| Jan 9 | Stifel | Maintains | Buy → Buy | — | $606.50 | $608.61 | +0.3% | +2.0% | +1.5% | +0.1% | +2.5% | +3.0% |
| Jan 7 | TD Cowen | Maintains | Buy → Buy | — | $620.72 | $618.70 | -0.3% | -0.6% | -2.3% | -0.3% | -0.8% | -2.2% |
| Dec 15 | Wells Fargo | Maintains | Overweight → Overweight | — | $572.28 | $574.23 | +0.3% | +0.6% | -0.4% | -1.7% | -1.7% | -0.8% |
| Dec 11 | Citigroup | Upgrade | Neutral → Buy | — | $573.81 | $576.62 | +0.5% | +0.9% | -0.3% | +0.4% | -0.6% | -2.0% |
| Dec 8 | KeyBanc Capital Markets | Upgrade | Sector Weight → Overweight | — | $572.77 | $570.80 | -0.3% | -0.8% | -1.7% | +0.2% | +1.1% | -0.1% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $585.15 | $581.94 | -0.5% | -0.8% | -0.8% | -1.7% | -2.1% | -2.9% |
| Dec 1 | HSBC | Upgrade | Hold → Buy | — | $590.83 | $594.85 | +0.7% | -1.0% | -1.8% | -1.8% | -2.6% | -3.1% |
| Oct 29 | Argus | Maintains | Buy → Buy | — | $557.63 | $558.31 | +0.1% | +0.1% | -0.3% | +1.8% | +1.3% | +1.4% |
| Oct 28 | Morgan Stanley | Maintains | Overweight → Overweight | — | $563.78 | $564.13 | +0.1% | -1.1% | -1.0% | -1.3% | +0.6% | +0.2% |
| Oct 23 | TD Cowen | Maintains | Buy → Buy | — | $567.20 | $567.90 | +0.1% | +0.8% | +0.9% | -0.6% | -1.7% | -1.6% |
| Oct 23 | Wells Fargo | Maintains | Overweight → Overweight | — | $567.20 | $567.90 | +0.1% | +0.8% | +0.9% | -0.6% | -1.7% | -1.6% |
| Oct 23 | Citigroup | Maintains | Neutral → Neutral | — | $567.20 | $567.90 | +0.1% | +0.8% | +0.9% | -0.6% | -1.7% | -1.6% |
| Oct 23 | UBS | Maintains | Neutral → Neutral | — | $567.20 | $567.90 | +0.1% | +0.8% | +0.9% | -0.6% | -1.7% | -1.6% |
| Oct 23 | Barclays | Maintains | Overweight → Overweight | — | $567.20 | $567.90 | +0.1% | +0.8% | +0.9% | -0.6% | -1.7% | -1.6% |
| Oct 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $557.99 | $555.50 | -0.4% | +1.7% | +2.5% | +2.6% | +1.0% | -0.1% |
| Oct 9 | JP Morgan | Maintains | Overweight → Overweight | — | $536.19 | $533.74 | -0.5% | -0.3% | -2.1% | -2.2% | -1.9% | -1.6% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $543.95 | $542.68 | -0.2% | -0.9% | -1.4% | -1.7% | -3.5% | -3.6% |
| Oct 2 | Barclays | Maintains | Overweight → Overweight | — | $530.73 | $525.71 | -0.9% | -1.1% | +2.4% | +2.5% | +1.6% | +1.0% |
| Sep 11 | Barclays | Upgrade | Equal Weight → Overweight | — | $476.54 | $480.58 | +0.8% | +3.1% | +0.6% | -0.4% | +0.9% | -0.8% |
| Jul 24 | Barclays | Maintains | Equal Weight → Equal Weight | — | $466.71 | $466.67 | -0.0% | +1.8% | +2.5% | +3.9% | +3.3% | +2.3% |
| Jul 24 | Baird | Maintains | Outperform → Outperform | — | $466.71 | $466.67 | -0.0% | +1.8% | +2.5% | +3.9% | +3.3% | +2.3% |
| Jul 24 | Raymond James | Maintains | Outperform → Outperform | — | $466.71 | $466.67 | -0.0% | +1.8% | +2.5% | +3.9% | +3.3% | +2.3% |
| Jul 24 | UBS | Maintains | Neutral → Neutral | — | $466.71 | $466.67 | -0.0% | +1.8% | +2.5% | +3.9% | +3.3% | +2.3% |
| Jul 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $466.71 | $466.67 | -0.0% | +1.8% | +2.5% | +3.9% | +3.3% | +2.3% |
| Jul 18 | Baird | Maintains | Outperform → Outperform | — | $424.98 | $425.92 | +0.2% | -2.4% | -4.7% | +0.6% | +9.8% | +11.8% |
| Jul 11 | Scotiabank | Upgrade | Sector Perform → Sector Outperform | — | $430.73 | $430.25 | -0.1% | +1.0% | -1.3% | -3.0% | -3.3% | -1.3% |
| Jul 9 | UBS | Downgrade | Buy → Neutral | — | $426.17 | $422.20 | -0.9% | -1.5% | +1.1% | +2.0% | -0.2% | -1.9% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $418.70 | $418.58 | -0.0% | +1.8% | +0.3% | +2.9% | +3.9% | +1.6% |
| Jun 24 | Barclays | Maintains | Equal Weight → Equal Weight | — | $400.21 | $401.80 | +0.4% | +1.0% | +2.6% | +3.0% | +2.0% | +1.3% |
| Apr 29 | Argus | Maintains | Buy → Buy | — | $421.34 | $421.82 | +0.1% | +1.5% | +1.8% | -0.3% | +0.5% | +0.2% |
| Apr 25 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $426.66 | $426.12 | -0.1% | -0.6% | -1.2% | +0.2% | +0.5% | -1.6% |
| Apr 24 | RBC Capital | Maintains | Outperform → Outperform | — | $431.64 | $430.00 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% |
| Apr 24 | Evercore ISI | Maintains | Outperform → Outperform | — | $431.64 | $430.00 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% |
| Apr 24 | Baird | Maintains | Outperform → Outperform | — | $431.64 | $430.00 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% |
| Apr 24 | Wells Fargo | Maintains | Overweight → Overweight | — | $431.64 | $430.00 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% |
| Apr 24 | Stifel | Maintains | Buy → Buy | — | $431.64 | $430.00 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% |
| Apr 24 | UBS | Maintains | Buy → Buy | — | $431.64 | $430.00 | -0.4% | -1.2% | -1.7% | -2.4% | -1.0% | -0.6% |
| Apr 17 | Wells Fargo | Maintains | Overweight → Overweight | — | $436.79 | $434.54 | -0.5% | -2.1% | -3.4% | -0.5% | -1.2% | -2.3% |
| Apr 10 | Barclays | Maintains | Equal Weight → Equal Weight | — | $453.55 | $446.40 | -1.6% | -5.8% | -3.4% | -0.9% | -2.8% | -3.7% |
| Mar 4 | Citigroup | Maintains | Neutral → Neutral | — | $523.64 | $523.02 | -0.1% | -1.4% | +0.1% | +0.8% | +1.5% | +0.6% |
| Feb 3 | Scotiabank | Maintains | Sector Perform → Sector Perform | — | $597.75 | $593.13 | -0.8% | -0.7% | -2.9% | -2.6% | -4.2% | -4.4% |
| Feb 3 | Raymond James | Maintains | Outperform → Outperform | — | $597.75 | $593.13 | -0.8% | -0.7% | -2.9% | -2.6% | -4.2% | -4.4% |
| Jan 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $606.74 | $599.87 | -1.1% | -1.5% | -2.1% | -4.3% | -4.0% | -5.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Apr 27, 2026 | Pettiti GianlucaOff | President & COO | Sell | 400 | $462.66 | $185K | 25,050 | +2.72% | +1.43% |
8-K
Thermo Fisher Scientific, Inc. -- 8-K Filing
Thermo Fisher Scientific reported first quarter 2026 earnings results, with contact information provided for investor inquiries regarding the company's financial performance.
Apr 23
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
A carefully negotiated executive departure with strict confidentiality provisions suggests potential internal conflict or performance issues, warranting investor scrutiny of management stability and upcoming leadership announcements.
Apr 1
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
An experienced diagnostics executive joining PostiveID (PSTV) as a leader strengthens management credibility and operational capability, potentially improving execution in the diagnostics sector.
Mar 26
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Thermo Fisher's $8.9 billion acquisition of Clario expands its clinical trial capabilities and diversifies revenue streams, but investors should monitor integration execution and earnout obligations that could increase total costs.
Mar 24
8-K
Unknown — 8-K Filing
Aurinia's executive leadership transition with a new COO appointment signals operational restructuring; the CEO's voluntary compensation waiver suggests confidence in turnaround strategy, potentially reducing near-term cash burn.
Mar 23
8-K · 1.01
! Medium
Thermo Fisher Scientific, Inc. -- 8-K 1.01: Financing / Debt Agreement
Thermo Fisher Scientific secured a financing arrangement with Deutsche Bank Securities, potentially providing capital access for operations, acquisitions, or debt refinancing activities.
Feb 12
Data updated apr 27, 2026 5:05am
· Source: massive.com